Drug-induced QT-interval prolongation: Considerations for clinicians

Pharmacotherapy

Volumn 30, Issue 7, 2010, Pages 684-701

  Li, Edward C ^a   Esterly, John S ^b,c   Pohl, Shaunte ^c,d   Scott, Shane D ^e   McBride, Brian F ^f  

^a National Comprehensive Cancer Network   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BAXTER HEALTHCARE CORPORATION   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antiarrhythmic agents; Arrhythmia; Atrial fibrillation; Pharmacogenomics; QT interval; QT prolongation; Sudden cardiac death; Torsade de pointes

Indexed keywords

AMIODARONE; ARIPIPRAZOLE; CHLORPROMAZINE; CIPROFLOXACIN; CLARITHROMYCIN; CLOZAPINE; DOFETILIDE; DRONEDARONE; ERYTHROMYCIN; FLUCONAZOLE; HALOPERIDOL; IBUTILIDE; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; MAGNESIUM; METHADONE; MEXILETINE; MOXIFLOXACIN; OLANZAPINE; PALIPERIDONE; PENTAMIDINE; PROPAFENONE; QUETIAPINE; RANOLAZINE; RISPERIDONE; SOTALOL; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE; ANTIARRHYTHMIC AGENT; DRUG;

ACTION POTENTIAL; DIARRHEA; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; NAUSEA; NONHUMAN; OPIATE ADDICTION; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; STABLE ANGINA PECTORIS; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; COMPLICATION; DEATH, SUDDEN, CARDIAC; DIAGNOSTIC USE; ELECTROCARDIOGRAPHY; HEART; HEART ARRHYTHMIA; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; HEART; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 77954117353     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.7.684     Document Type: Review

References (203)

1. Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
2. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci [in French]. Arch Mal Coeur Vaiss 1966;59: 263-72.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287: 2215-20.
4. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363-9.
5. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. Molecular determinants of hERG channel block. Mol Pharmacol 2006;69:1709-16.
6. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000;97:12329-33.
7. Straus SMJM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Col Cardiol 2006;47:362-7.
8. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-94.
9. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-65.
10. Kr: implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-11.
11. K-blocking drugs. Circulation 2001;103:2207-12.
12. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-4. (Pubitemid 26307281)
13. Houltz B, Darpo B, Swedberg K, et al. Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization. Europace 2000;2:20-31.
14. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691-6. (Pubitemid 30397542)
15. Goldberg R, Bengtson J, Chen Z, Anderson K, Locati E, Levy D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (the Framingham heart study experience). Am J Cardiol 1991;67:55-8.
16. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study - a randomized trial. JAMA 2006;295:165-71.
17. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351:2384-91.
18. Wyse DG, Waldo AL, DiMarco JP, for the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
19. Corley SD, Epstein AE, DiMarco JP, for the AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109:1509-13.
20. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
21. Straus SMJM, Sturkenboom MCJM, Bleumink GS, et al. Noncardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12.
22. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
23. Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 2006;109:273-4.
24. Kmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol 2007;30:1043-6.
25. Hill SL, Evangelista J-aK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI. Proarrhythmia associated with cisapride in children. Pediatrics 1998;101:1053-6.
26. Piquette RK. Torsade de pointes induced by cisapride/ clarithromycin interaction. Ann Pharmacother 1999;33:22-6.
27. Roden DM, Balser JR, George AL Jr, Anderson ME. Cardiac ion channels. Annu Rev Physiol 2002;64:431-75.
28. Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J 2008;15:100-21.
29. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110: 904-10.
30. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:1029-34.
31. Roden DM. Pharmacogenomics of cardiac arrhyhthmias and impact on drug therapy. In: Zipes D, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. Philadelphia: Saunders, 2004:471-8.
32. Yetkin E, Senen K, Ileri M, et al. Diurnal variation of QT dispersion in patients with and without coronary artery disease. Angiology 2001;52:311-16.
33. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003;82:282-90.
34. + current in cardiac cells. Circ Res 1997;80:782-9.
35. Zhang S, Sawanobori T, Adaniya H, Hirano Y, Hiraoka M. Dual effects of external magnesium on action potential duration in guinea pig ventricular myocytes. Am J Physiol Heart Circ Physiol 1995;268:H2321-8.
36. McBride BF, Min B, Kluger J, et al. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol 2006;11:163-9.
37. Haigney MC, Berger R, Schulman S, et al. Tissue magnesium levels and the arrhythmic substrate in humans. J Cardiovasc Electrophysiol 1997;8:980-6.
38. Rodriguez I, Kilborn MJ, Liu X-K, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285:1322-6. (Pubitemid 32216147)
39. Gowda RM, Khan IA, Punukollu G, Vasavada BC, Sacchi TJ, Wilbur SL. Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol 2004;95:219-22.
40. Drici M-D, Knollmann BC, Wang W-X, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280:1774-6.
41. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
42. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005;85:1205-53.
43. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-13. (Pubitemid 32322230)
44. Dubin D. Recording the EKG. In: Rapid interpretaion of EKG's, 6th ed. Hong Kong: Cover Publications, Inc., 2000:31-54.
45. Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004;110:3661-6.
46. Milberg P, Ramtin S, Mönnig G, et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol 2004;44:278-86.
47. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001;104:2722-7.
48. Moro S, Ferreiro M, Celestino D, Medei E, Elizari MV, Sicouri S. In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle. J Cardiovasc Pharmacol Ther 2007;12:314-21.
49. Drouin E, Lande G, Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 1998;32:1063-7.
50. Knollmann BC, Casimiro MC, Katchman AN, et al. Isoproterenol exacerbates a long QT phenotype in Kcnq1-deficient neonatal mice: possible roles for human-like KCNQ1 isoform 1 and slow delayed rectifier K+ current. J Pharmacol Exp Ther 2004;310:311-18.
51. Jost N, Virag L, Bitay M, et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 2005;112:1392-9.
52. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome : effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998;98:2314-22.
53. Zeng J, Rudy Y. Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys J 1995;68:949-64.
54. Kozhevnikov DO, Yamamoto K, Robotis D, Restivo M, El- Sherif N. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation 2002;105:1128-34.
55. El-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ Res 1996;79:474-92. (Pubitemid 26276908)
56. Hryshko L. Membrane pumps and exchangers. In: Zipes D, Jalife J, eds. Cardiac electrophysiology: from cell to bedside, 4th ed. Philadelphia: Saunders, 2004:47-8.
57. 2+ exchange current in guinea-pig cardiac myocytes. Br J Pharmacol 2000;131:80-4.
58. Watanabe Y, Kimura J. Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 2008;377:371-6.
59. The ICH Expert Working Group. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, 2005. Available from http://www.ich.org/LOB/media/MEDIA1476.pdf. Accessed October 13, 2008.
60. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006;3:1003-7.
61. Sagie A, Larson M, Goldberg R, Bengtson J, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham heart study). Am J Cardiol 1992;70: 797-801.
62. Yan G-X, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98:1928-36. (Pubitemid 28509291)
63. Viskin MDS, Heller MDK, Barron MDHV, et al. Postextrasystolic U wave augmentation, a new marker of increased arrhythmic risk in patients without the long QT syndrome. J Am Coll Cardiol 1996;28:1746-52.
64. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 2009;54:143-9.
65. Moss A, Schwartz P, Crampton R, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991;84:1136-44.
66. Bednar M, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
67. European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients With atrial fibrillation). J Am Coll Card 2006;48:854-906. (Erratum in J Am Coll Cardiol 2007;50:562.)
68. Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 2008;51:843-9.
69. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007;49:986-92.
70. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77.
71. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: pharmacological intervention in atrial fibrillation (PIAF) - a randomised trial. Lancet 2000;356: 1789-94.
72. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40.
73. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (catheter ablation for the cure of atrial fibrillation study). Eur Heart J 2006;27:216-21.
74. Roux J. Antiarrhythmics after ablation of atrial fibrillation (5A) study. Late-breaking clinical trials session. Presented at the Heart Rhythm Society 2008 scientific sessions, San Francisco, CA, May 15, 2008.
75. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
76. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian implantable defibrillator study (CIDS). Am Heart J 2002;144:282-9.
77. Kamphuis HCM, de Leeuw JRJ, Derksen R, Hauer RNW, Winnubst JAM. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace 2003;5:381-9.
78. Mazur A, Anderson ME, Bonney S, Roden DM. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 2001;37:1100-5.
79. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999;340:1855-62.
80. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
81. Zhang N, Guo JH, Zhang HCh, Li XB, Zhang P, Xn YN. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract 2005;59:1395-400.
82. Fragakis N, Papadopoulos N, Papanastasiou S, et al. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. Pacing Clin Electrophysiol 2005;28:954-61.
83. Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001;103:253-7.
84. Chen YJ, Hsieh MH, Chiou CW, Chen SA. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J Cardiovasc Pharmacol 1999;34: 237-47.
85. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993;22:540-9. (Pubitemid 23286749)
86. McBride BF, Yang T, Roden DM. Influence of the G2677T/ C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J 2009;9:194-201.
87. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.
88. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol 1999;84:270-7.
89. Groh WJ, Gibson KJ, McAnulty JH, Maylie JG. β-Adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol. Circulation 1995;91:262-4.
90. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90.
91. Bayer Healthcare Pharmaceuticals. Betapace AF (sotalol) prescribing information. Wayne, NJ; 2007. Available from http://www.betapaceaf.com/PDF/ BetapaceAF-PI.pdf. Accessed November 17, 2008.
92. Pfizer, Inc. Tikosyn (dofetilide) package insert. New York, NY; 2008. Available from http://www.tikosyn.com/pdf/PI-tikosyn.pdf. Accessed November 17, 2008.
93. Allen MJ, Nichols DJ, Oliver SD. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 2000;50:247-53.
94. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 2005;77:572-82.
95. Wu Y, Carlsson L, Liu T, Kowey Pr, Yan G-X. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 2005;16:898-904.
96. Kirchhof P, Milberg P, Eckardt L, Breithardt GN, Haverkamp W. Effect of sotalol and acute ventricular dilatation on action potential duration and dispersion of repolarization after defibrillation shocks. J Cardiovasc Pharmacol 2003;41:640-8.
97. Kaye DM, Dart AM, Jennings GL, Esler MD. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J Am Coll Cardiol 1999;33:1553-9.
98. Lalevée N, Barrère-lemaire S, Gautier P, Nargeot J, Richard S. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 2003;14:885-90.
99. Sato R, Koumi S, Singer DH, et al. Amiodarone blocks the inward rectifier potassium channel in isolated guinea pig ventricular cells. J Pharmacol Exp Ther 1994;269:1213-19. (Pubitemid 24204207)
100. Le Bouter S, El Harchi A, Marionneau C, et al. Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart. Circulation 2004;110:3028-35.
101. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
102. Singh BN, Connolly SJ, Crijns HJGM, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99.
103. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008;5:1019-26.
104. Kumar K, Nearing B, Bartoli C, Kwaku K, Belardinelli L, Verrier R. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol 2008;19:1073-9.
105. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-16.
106. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52.
107. Duff H, Roden D, Primm R, Oates J, Woosley R. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983;67:1124-8. (Pubitemid 13099084)
108. Chézalviel-Guilbert F, Davy J-M, Poirier J-M, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol 1995;26:787-92.
109. Frederique C-G, Deplanne V, Davy J-M, et al. Combination of sotalol and quinidine in a canine model of torsades de pointes. J Cardiovasc Electrophysiol 1998;9:498-507.
110. Caron MF, Kluger J, Tsikouris JP, Ritvo A, Kalus JS, White CM. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy 2003;23: 296-300.
111. Sueta CA, Clarke SW, Dunlap SH, et al. Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. Circulation 1994;89:660-6.
112. Coleman C, Kalus J, Caron M, Kluger J, White C. Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients. Am J Health Syst Pharm 2004;61:685-8.
113. American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovscular care. Part 7.2. Management of cardiac arrest. Circulation 2005;112(suppl 1):IV-58-66.
114. Malfatto G, Zaza A, Forster M, Sodowick B, Danilo PJ, Rosen M. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and Ndepropylpropafenone. J Pharmacol Exp Ther 1988;246: 419-26.
115. Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. Am J Cardiol 2004;94:1563-6.
116. Bellandi F, Simonetti I, Leoncini M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001;88:640-5. (Pubitemid 32831097)
117. Merot J, Charpentier F, Poirier J-M, Coutris G, Weissenburger J. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. Cardiovasc Res 1999;44:303-14.
118. Darke S, Kaye S, Duflou J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction 2006;101:1771-7.
119. Puigdollers E, Domingo-Salvany A, Brugal T, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse 2004;39:1353-68.
120. Berkman L, Blummenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 2003;289:3106-16.
121. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. Arch Intern Med 2000;160:1261-8.
122. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. British J Psychiatry 2007;190:460-6.
123. Bär K-J, Koschke M, Boettger MK, et al. Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. Schizophr Res 2007;95:115-23.
124. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 2007;90:162-73.
125. Cohn T, Prud'homme D, Steiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60.
126. Saari K, Linderman S, Viilo K, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study. J Clin Psychiatry 2005;66:559-63.
127. Stajer D, Mozina H, Noc M, Rode P. Correlation between QTc interval duration and left ventricular systolic dysfunction in patients with acute myocardial infarction. J Electrocardiol 1993;26:333-40.
128. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719-28.
129. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacotherapy 2005;25:1523-9.
130. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-95.
131. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MCP. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469-75.
132. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009;361:777-86.
133. Moore TA, Buchanan RW, Buckley PF, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-62.
134. Marder S. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 2006; 67(suppl 10):13-21. (Pubitemid 44433622)
135. Crumb W, Ekins S, Sarazan R, et al. Effects of antipsychotic drugs on Ito ,INa,Isus,IK1, and hERG: QT prolongation, structure activity relationship , and network analysis. Pharm Res 2006;23:1133-43.
136. Kongsamut S, Kang J, Chen X-L, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41.
137. Anonymous. Study 054. Briefing document for Zeldox capsules (ziprasidone HCL). FDA psychopharmacological drugs advisory committee, July 19, 2000. Available from http:// www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf.
138. Thomas D, Wu K, Kathofer S, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 2003;139:567-74. (Pubitemid 36819626)
139. Brown CS, Farmer RG, Soberman JE, Eichner SF. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004;43:33-56.
140. Mörl D, Agneter E, Krivanek P, Koppatz K, Todt H. Dual rate dependent cardiac electrophysiological effects of haloperidol: slowing of intraventricular conduction and lengthening of repolarization. J Cardiovasc Pharmacol 2003;41:870-9.
141. Hoehns JD, Stanford RH, Geraets DR, Skelly KS, Lee HC, Gaul BL. Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy 2001;21:871-83.
142. Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001;41:1310-18.
143. Dorado P, Berecz R, Penas-Lledo EM, Llerena A. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin Drug Metab Toxicol 2007;3:9-19.
144. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 1999;33:1046-50.
145. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anesth 2000;47:251-4.
146. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238-40.
147. Czekalla J, Beasley C, Dellva M, Berg P, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001;62:191-8. (Pubitemid 32270094)
148. + channel blockade by the antipsychotic drug thioridazine: an obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun 2006;351:273-80.
149. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in shortterm, placebo-controlled trials. Schizophr Res 2003;61:123-36.
150. Furst BA, Champion KM, Pierre JM, Wirshing DA, Wirshing WC. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biologic Psychiatry 2002;51:264-5.
151. Vieweg WVR, Schneider RK, Ma W. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 2005;112:318-22.
152. Raviña T, Raviña P, Gutierrez J. Acquired long QT syndrome: risperidone-facilitated triggered activity and torsades de pointes during complete AV block. Int J Cardiol 2007;116: 416-20.
153. Llerena A, Berecz R, Dorado P, de la Rubia A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004;18:189-93.
154. Vieweg W. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 2003;5:205-15.
155. Simko J, Csilek A, Karaszi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection 2008;36:194-206.
156. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration adverse event reporting system. Clin Infect Dis 2002;35:197-200.
157. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med 2006;17:254-9.
158. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89:235-8.
159. Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003;254:1-7.
160. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide
161. Rubart M, Pressler M, Pride H, Zipes D. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-44. (Pubitemid 23296931)
162. Antzelevitch CS, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996;28:1836-48.
163. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218-25.
164. Austin KL, Mather LE, Philpot CR, McDonald PJ. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-9.
165. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ 1990;300:1375-6.
166. Tschida SJ, Guay DRP, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996;16:663-74.
167. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998;104:395-6.
168. Kamochi H, Nii T, Eguchi K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421-2.
169. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
170. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317-24.
171. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999;22:672-4.
172. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. Lancet 1997;349:326-7.
173. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997;30:437-9.
174. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091-124.
175. Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H. Risk of torsades de pointes with non-cardiac drugs: prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ 2001;322:46-7.
176. Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 2001;87:231-4. (Pubitemid 33815528)
177. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658-66.
178. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52-6.
179. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole [case report]. Ann Intern Med 1999;131:797.
180. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother 2001;35:432-4.
181. Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy 2002;22:1632-7.
182. Tatetsu H, Asou N, Nakamura M, et al. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol 2006;81:366-9.
183. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004;39:e49-52.
184. Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR. Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007;9:33-6.
185. Eiden C, Peyriere H, Tichit R, et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther 2007;32:321-4.
186. Strevel E, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-71.
187. National Cancer Institute. Cancer therapy evaluation program, common terminology criteria for adverse events, version 4.0. Available from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.02-2009-09-15-QuickReference-8.5x11. pdf.
188. Bristol-Myers Squibb. Sprycel (dasatinib) prescribing information. Princeton, NJ; 2009.
189. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) prescribing information. East Hanover, NJ; 2007.
190. Pfizer Inc. Sutent (sunitinib) prescribing information. New York, NY; 2008.
191. Buckstein R, Meyer RM, Seymour L, et al. Phase II testing of sunitinib: the National Cancer Institute of Canada clinical trials group IND program trials IND182-185. Curr Oncol 2007;14:154-61.
192. National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology, acute myeloid leukemia (version 1.2010). Fort Washington, PA: National Comprehensive Cancer Network, 2009.
193. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
194. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97:1514-16.
195. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685-96.
196. He J, Kargacin ME, Kargacin GJ, Ward CA. Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2003;285:H661-8.
197. Liu X-K, Katchman A, Ebert SN, Woosley RL. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998;287:877-83. (Pubitemid 29131595)
198. Slovacek L, Ansorgova V, Macingova Z, Haman L, Petera J. Tamoxifen-induced QT interval prolongation. J Clin Pharm Ther 2008;33:453-5.
199. Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm 2007;64:1174-86.
200. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007;107:531-6.
201. Habib AS, Gan TJ. Food and Drug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003;96:1377-9.
202. Merck & Co., Inc. Zolinza (vorinostat) prescribing information. Whitehouse Station, NJ; 2009.
203. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 2007;035:1060-3.